Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided system that combines magnetic resonance imaging (MRI) with precise prostate ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...

Long-used imaging strategies such as computed tomography (CT) and bone scintigraphy (BS) to detect lymph node and bone metastases have significant limitations and disadvantages. Newly emerging ...

The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer. Key areas include expansion in radioligand therapy and ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting ...